MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC ...
Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...
Galea, H. , Perry, M. and Jones, P. (2026) Characterising Irritable Bowel Syndrome: An Exploratory Cross-Sectional Study .
IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...
In this study, 3,319 unselected, pan-cancer Jordanian patients diagnosed between April 2021 and September 2022 received GGT. Pathogenic germline variant (PGV) frequency among patients who were ...
In a recent study published in the journal Mindfulness, researchers examine the prevalence and effects of emergent phenomena (EP), their forms, the balance of positive and negative repercussions, and ...